Tag: Concord Biotech

22 Sep
Concord Biotech Shares Up 3% on Positive Outlook from Analysts
Concord Biotech shares were trading 3% higher on September 22nd after Kotak Institutional Equities and Antique Broking initiated coverage of the company with a positive outlook on the stock. Both brokerages cited the company's expertise in high entry barrier fermentation active pharmaceutical ingredients (API) segment and strong underlying demand trends as key reasons for their bullish stance. Kotak Institutional Equities has an 'add' rating on the company's stock and has set a target price of Rs 1,110 per share, while Antique Brokings has a 'buy' rating and has set a target price of Rs 1,340 per share.